What is the GUIDE.MRD Patient Advisory Board?
The GUIDE.MRD Patient Advisory Board (PAB) has been established to facilitate patient engagement and co-creation across all project Work Packages, namely, to understand patients’ needs and experiences along the care pathway, and particularly post-surgery and prior to (possible) relapse.
The PAB consists of eleven members from across Europe, including patient representatives, representatives of EU patient organisations, carers and individuals living with cancer, representing lung, colorectal, and pancreatic cancers. The PAB is co-led by Digestive Cancers Europe (DiCE) and The Synergist, with support from Lung Cancer Europe (LuCE), and with the participation of all GUIDE.MRD consortium members.
The role of the GUIDE.MRD PAB is to provide patient community insights and advice and contribute to co-creation across the project. The PAB will ensure that patients’ interests and priorities are considered and that the outcomes of GUIDE.MRD will provide benefits to patients, patient communities, and society as a whole.
The contributions of the PAB members are valuable and are not limited to tasks within the GUIDE.MRD project itself. Involvement throughout the project will ensure the conduct of patient-centred research and will empower PAB members as advocates for ctDNA testing and thought leaders on liquid biopsies in their respective organisations and networks.